An outbreak caused by the SARS-CoV-2 Delta (B.1.617.2) variant in a care home after partial vaccination with a single dose of the COVID-19 vaccine Vaxzevria, London, England, April 2021
Sarah Williams, Amoolya Vusirikala, Shamez Ladhani, Elena Fernandez Ruiz De Olano, Nalini Iyanger, Felicity Aiano, Kelly Stoker, G. Gopal Rao, Laurence John, Bharat Patel, Nick Andrews, Gavin Dabrera, Mary Ramsay, Kevin Brown, Jamie Lopez Bernal, Vanessa Saliba
Abstract
We investigated a COVID-19 outbreak of the SARS-CoV-2 Delta variant of concern in a London care home, where 8/21 residents and 14/21 staff had received a single dose of Vaxzevria (ChAdOx1-S; AstraZeneca) vaccine. We identified 24 SARS-CoV-2 infections (16 residents, 8 staff) among 40 individuals (19 residents, 21 staff); four (3 residents, 1 staff) were hospitalised, and none died. The attack rate after one vaccine dose was 35.7% (5/14) for staff and 81.3% (13/16) for residents.
Topics & Concepts
OutbreakCoronavirus disease 2019 (COVID-19)MedicineVaccinationSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakFamily medicineEmergency medicineVirologyInternal medicineInfectious disease (medical specialty)DiseaseSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19